US-based clinical-stage biopharmaceutical company SFA Therapeutics, Inc. announced on Wednesday that it has named Dr Ananda Gubbi, PhD as its new director of Biostatistics.

In the new role, Dr Gubbi is to direct biostatistics at the company to help it develop its drug candidates more effectively.

Dr Gubbi, a seasoned leader in biostatistics, has more than 25 years of experience in leading complex statistical analyses for preclinical and Phase one through Phase IV clinical studies. He has worked as a consultant for biostatistics in the pharmaceutical industry and at Slippery Rock University.

Previously, Dr Gubbi earlier served as the associate director, Biostatistics, at CPC Clinical Services, biostatistician at Amgen, Teva Pharmaceuticals, Kite Pharmaceuticals, Genentech, Sanofi-Aventis Pharmaceuticals, Schering-Plough, Pharmacia-Upjohn and Boehringer Ingelheim. He has also served as a statistical reviewer at the FDA where he developed his skillset in clinical trials.